News >

Pembrolizumab Monotherapy Shows Potential in Non-Clear Cell RCC

Kristi Rosa
Published: Monday, Jul 22, 2019

David McDermott, MD

David McDermott, MD
Data from the KEYNOTE-427 trial with pembrolizumab (Keytruda) monotherapy may pave the way for the use of immunotherapy in patients with non-clear cell renal cell carcinoma (RCC)—an area for which there are no currently approved therapies available, said David F. McDermott, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication